Biogen Inc. buy Royal Bank of Canada
Start price
13.02.25
/
50%
€130.50
Target price
13.02.26
€215.73
Performance (%)
16.32%
Price
02.01.26
€151.80
Summary
This prediction is currently active. The prediction currently has a performance of 16.32%. This prediction currently runs until 13.02.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biogen Inc. | 2.360% | 2.360% |
| iShares Core DAX® | 0.869% | 3.389% |
| iShares Nasdaq 100 | -0.852% | -2.157% |
| iShares Nikkei 225® | 0.436% | 1.060% |
| iShares S&P 500 | -0.122% | -0.270% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Royal Bank of Canada from $231.00 to $225.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat